ArticleIndian journal of psychiatry2026
Post-COVID neuropsychiatric symptoms in India: Prevalence, risk factors, and persistence.
Article in Indian journal of psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The global research has actively investigated the post-COVID neuropsychiatric symptoms (PCNS). There is a paucity of studies from India that explore long-term PCNS. Aim: This study aims to estimate prevalence, types of PCNS, associated factors (sociodemographic factors, life events, COVID-19-related variables, and vaccination status) and persistence of PCNS after two years. Methods: A cross-sectional study was conducted from October 2022 to October 2023 in a tertiary care hospital. A total of 2,281 randomly selected individuals with reverse transcription polymerase chain reaction-positive for COVID-19 were screened for PCNS. Among 927 participants consented to and completed the telephonic screening for PCNS. Structured clinical interviews for DSM-5-Research Version and World Health Organization-Post-COVID Case Report Form were applied. Descriptive statistics and binary logistic regression analysis were used for data analysis. Results: Median age of individuals was 34 years, and 51.3% being female. Only 21.6% had lifetime PCNS, and 7.3% had persistent PCNS at two years of COVID-19. The common lifetime PCNS were persistent fatigue (15.6%), reduced smell (5.9%), reduced taste (4.8%), anxiety (4.3%), insomnia (3.6%), depressed mood (2.6%), cognitive symptoms (2.6%), and persistent muscle pain (2.6%). The logistic regression analysis revealed a positive association of lifetime PCNS with female gender, preexisting medical comorbidities, symptomatic COVID-19, oxygen supplementation, repeated infections, and life events. Full or partially vaccinated against COVID-19 appeared to be protective against PCNS. Conclusion: About one in five individuals developed lifetime PCNS following COVID. Among them, one in three had persistent PCNS after two years of COVID. Female gender, life events, severity of COVID-19, repeated infection, and Vaccine-naïve status were associated with the development of PCNS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.